Aurobindo Pharma Sets Up Auropharm Overseas to Expand Pharma Manufacturing, Marketing
Hyderabad: Aurobindo Pharma Limited has incorporated a new wholly owned subsidiary, Auropharm Overseas Limited, in India, with the objective of undertaking manufacturing and marketing operations in India and foreign countries.
Auropharm Overseas Limited was incorporated on August 13, 2026, and therefore has no applicable turnover history. The new entity belongs to the pharmaceuticals industry and has been established as a wholly owned subsidiary of Aurobindo Pharma.
According to the company's disclosure, the incorporation of Auropharm Overseas Limited is considered a related party transaction, as the entity is a wholly owned subsidiary of Aurobindo Pharma. However, the company's promoters and promoter group do not have any interest in the transaction.
The primary objective behind establishing the subsidiary is to undertake manufacturing and marketing operations in India as well as foreign countries. The company has not indicated any business activity outside the pharmaceutical sector for the newly incorporated entity.
Aurobindo Pharma stated that no governmental or regulatory approvals are required for the incorporation. The indicative time period for completion of the acquisition has been marked as not applicable, as the transaction relates to the incorporation of a new wholly owned subsidiary rather than an acquisition of an existing entity.
The nature of consideration for the incorporation is 100% subscription to the share capital in cash. The initial subscription to the share capital is ₹10,00,000, divided into 1,00,000 equity shares of ₹10 each. Aurobindo Pharma holds 100% shareholding and control in the newly incorporated company.
Auropharm Overseas Limited is a newly incorporated company, and consequently its history of turnover for the previous three years is not available. The disclosure specifically confirms that the company was incorporated in India on August 13, 2026.
The incorporation of Auropharm Overseas Limited establishes a new wholly owned pharmaceutical subsidiary of Aurobindo Pharma, with its stated business objective focused on manufacturing and marketing operations in India and foreign countries. The subsidiary has been funded through an initial cash subscription of ₹10 lakh for 1 lakh equity shares, with Aurobindo Pharma holding 100% control.
